First of all, BSX and GDT each have insurance to provide for defense of any claims, class action or otherwise. The insurance carrier will carry the burden of providing money for defense.
However, should BSX or GDT lose in court the ramifications depend on the limits of coverage they have. You can bet both companies have a primary insurerer and several re-insureers. Reinsurance is used by companies to 'spread out the risk', so no one insurance company takes a huge hit.
So, don't look at each companies bottom line and start subtracting court costs, etc. you have to take in their first line of financial protection: their insurance carriers.
Their respective insurance companies will respond first to any suit and should any judgement be against either company within their limits, the insurance company will pay any outlay required.
However, if any judgement is against either company (they'll be appealed most likely) and go OVER their limits of insurance, then the money comes 'out of pocket'.
Down on high volume again. These guys are a bunch of clowns, they have a new recall about every day. People just assume BSX products will fail now. With so much alternatives, and competition on the market I don't think anyone would intentionally use their broken junk. Still waiting to see if the FDA will punish them for lying. But I expect we will see major losses after the 6 class action lawsuits, there is not much money to pay for all the leagal fees and injunctions.
BSX is screwed as are the bagholders. Come on fess up who was the bagholder who bought today at the top? This is going to be a game of musical chairs and you will be left standing when the music stops ha ha, up on no volume means this stock will fall like a rock next week. The long term trend is down and Guidant and BSX make a great team of missing estimates and killing people with defective products.
Why pay top dollar for sheeeeet this is going to be a $10 stock after a few more quarters of losses.
The surgeons in my town use the Terumo Pinnacle introducer sheaths every time they put in a stent or do any angioplasty. How do you suppose the "high margin/high revenue products like drug coated stents" are inserted? You need an introducer, Sherlock. Glidewires are used also during the procedure, sometimes more than one, depending on the circumstances. I've seen 3 or 4 opened up and used during a difficult case. All that adds up after a while. Glidewires are also used in urology cases at times. Those are just the ones I am most familiar with. They offer alot of other useful products. Hopefully BSX will be able to offer viable alternatives. If the buyout of GDT goes through, I would imagine GDT has some good products as alternatives. I'll check that out later.
These 'nuts and bolts' are low margin, generate little revenue and distract buyers and sellers from dealing with the high margin / high revenue products like drug coated stents and neuro devices. This is a very good move as BSX sales staff can concentrate on products that generate >70% margin. You exaggerate the value of bundling a few thousand in 'nuts and bolts' into million dollar contracts for high end products. (Go back to school.)
Looks like BSX fundamentals are unraveling. Apparently the insiders are selling tons and tons of stock at the lows for numerous reasons.
BSX is losing the truemo glidewire and glidecath
business by the early part of next year, these devices
are the nuts and bolts of both coronary and peripheral
procedures. They provide leverage in negotiating
whether a lab will be boston or cordis. W/O this line
JNJ has more to offer in bulk contracting to
hospitals, especially since they add the product line
of GDT into the mix. Aquisition of materials are the
greatest cost concern to an insitiution, and the
ability to reduce them is a powerful sales tool. Also,
the addition of Abbott Vascular, MDT and start-up
Connor Medical into the DES space will reduce margins,
and market share. Unfortunately BSX does not have any
organically developing assets to reverse this,
All the Scimed reps are younger people. This is the same everywhere, not just at BSX. Age discrimination may be illegal but hospitals do it anyway by hiring the young and forgetting the old.
Terumo exits: Any big loss here? Doesn't Guidant have the HiTorque Floppy? Who needs Terumo? Bye Bye to the old here also.
One thing I can't agree with you is the treatment of the older employees. The experience of Tom Dunigan is unfortunately not isolated. Check with any older employees 50 or older with 15 or more years of service if you can find any.
Shirley Long is an idiot for what she has most recently written.
Well I think your smarter than most of the idiots that post here, lets just say I am very disapointed in BSX management and products. I know that people have died because of their neglegence, and I will be joining the class action lawsuit to get money back that I have lost from being a former holder. I don't have anything to do with the law offices, nor does my husband. BSX has clearly been shown to put out defective products more than others.
Studies Give Edge To J&J Stent
NEW YORK - Johnson & Johnson has a better product than its rival, Boston Scientific, for holding open clogged arteries.
New data published in the two leading medical journals indicates that patients who receive Cypher, a drug-coated stent made by Johnson & Johnson (nyse: JNJ - news - people ), are far less likely to need a repeat surgery than those who get Taxus, a rivalstent from Boston Scientific (nyse: BSX - news - people ).
That's more bad news for Boston Scientific, which has seen shares drop 30% since September 2004 amid concerns over its over-reliance on drug-coated stents.
"There is a difference," says David J. Moliterno, a cardiologist at the University of Kentucky who wrote an editorial on the studies in The New England Journal of Medicine.
For all patients taken as a group, Moliterno says, those who receive Taxus are much more likely to need their procedure redone than those who receive Cypher.
High-risk patients, such as those with diabetes, also fare better with the Cypher stent, he says.
Samin Sharma, a cardiologist at the Mount Sinai School of Medicine, say she thinks most doctors would opt to use Cypher if it weren't for persistent manufacturing problems that can make the device harder for doctors to get. He notes that the evidence is consistent that Cypher is better at preventing arteries from reclogging.
The researchers found that patients receiving Cypher were at much lower risk of having their arteries reclose than those who received Taxus. The results are published in the current issue of The Journal of the American Medical Association. Says Firth, "I think the value of this product from a health economics standpoint is very clearly demonstrated."
Meanwhile, J&J says the U.S. Food and Drug Administration has visited new manufacturing plants that would finally allow it to churn out more Cypher stents--and it is waiting for the OK to start the assembly lines running.